|
Gene: TICAM1 |
Gene summary for TICAM1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TICAM1 | Gene ID | 148022 |
Gene name | toll like receptor adaptor molecule 1 | |
Gene Alias | IIAE6 | |
Cytomap | 19p13.3 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q8IUC6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
148022 | TICAM1 | C04 | Human | Oral cavity | OSCC | 6.21e-15 | 7.00e-01 | 0.2633 |
148022 | TICAM1 | C21 | Human | Oral cavity | OSCC | 1.74e-43 | 1.23e+00 | 0.2678 |
148022 | TICAM1 | C30 | Human | Oral cavity | OSCC | 1.66e-19 | 6.33e-01 | 0.3055 |
148022 | TICAM1 | C38 | Human | Oral cavity | OSCC | 5.34e-08 | 7.27e-01 | 0.172 |
148022 | TICAM1 | C43 | Human | Oral cavity | OSCC | 6.33e-28 | 5.60e-01 | 0.1704 |
148022 | TICAM1 | C46 | Human | Oral cavity | OSCC | 2.10e-20 | 6.21e-01 | 0.1673 |
148022 | TICAM1 | C57 | Human | Oral cavity | OSCC | 3.78e-43 | 1.14e+00 | 0.1679 |
148022 | TICAM1 | C08 | Human | Oral cavity | OSCC | 9.88e-31 | 6.57e-01 | 0.1919 |
148022 | TICAM1 | C86 | Human | Oral cavity | OSCC | 6.99e-04 | 1.02e+00 | 0.161 |
148022 | TICAM1 | C09 | Human | Oral cavity | OSCC | 1.52e-30 | 9.82e-01 | 0.1431 |
148022 | TICAM1 | LN38 | Human | Oral cavity | OSCC | 6.91e-04 | 8.71e-01 | 0.168 |
148022 | TICAM1 | LN46 | Human | Oral cavity | OSCC | 2.56e-26 | 9.97e-01 | 0.1666 |
148022 | TICAM1 | LP15 | Human | Oral cavity | LP | 5.07e-05 | 8.63e-01 | 0.2174 |
148022 | TICAM1 | LP17 | Human | Oral cavity | LP | 3.02e-03 | 4.56e-01 | 0.2349 |
148022 | TICAM1 | SYSMH1 | Human | Oral cavity | OSCC | 2.59e-05 | 1.91e-01 | 0.1127 |
148022 | TICAM1 | SYSMH2 | Human | Oral cavity | OSCC | 4.24e-08 | 2.50e-01 | 0.2326 |
148022 | TICAM1 | SYSMH3 | Human | Oral cavity | OSCC | 9.18e-14 | 3.30e-01 | 0.2442 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:0043254 | Colorectum | AD | regulation of protein-containing complex assembly | 148/3918 | 428/18723 | 2.64e-11 | 3.18e-09 | 148 |
GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
GO:0010506 | Colorectum | AD | regulation of autophagy | 111/3918 | 317/18723 | 3.57e-09 | 2.35e-07 | 111 |
GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
GO:0031396 | Colorectum | AD | regulation of protein ubiquitination | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
GO:0032092 | Colorectum | AD | positive regulation of protein binding | 33/3918 | 85/18723 | 1.22e-04 | 1.78e-03 | 33 |
GO:0006809 | Colorectum | AD | nitric oxide biosynthetic process | 30/3918 | 76/18723 | 1.72e-04 | 2.33e-03 | 30 |
GO:0043123 | Colorectum | AD | positive regulation of I-kappaB kinase/NF-kappaB signaling | 60/3918 | 186/18723 | 1.91e-04 | 2.56e-03 | 60 |
GO:0043122 | Colorectum | AD | regulation of I-kappaB kinase/NF-kappaB signaling | 76/3918 | 249/18723 | 2.17e-04 | 2.85e-03 | 76 |
GO:0046209 | Colorectum | AD | nitric oxide metabolic process | 31/3918 | 81/18723 | 2.61e-04 | 3.25e-03 | 31 |
GO:0010508 | Colorectum | AD | positive regulation of autophagy | 43/3918 | 124/18723 | 2.64e-04 | 3.27e-03 | 43 |
GO:2001057 | Colorectum | AD | reactive nitrogen species metabolic process | 31/3918 | 82/18723 | 3.37e-04 | 3.94e-03 | 31 |
GO:0007249 | Colorectum | AD | I-kappaB kinase/NF-kappaB signaling | 82/3918 | 281/18723 | 6.09e-04 | 6.40e-03 | 82 |
GO:0032481 | Colorectum | AD | positive regulation of type I interferon production | 23/3918 | 58/18723 | 8.82e-04 | 8.53e-03 | 23 |
GO:0045429 | Colorectum | AD | positive regulation of nitric oxide biosynthetic process | 17/3918 | 40/18723 | 1.66e-03 | 1.38e-02 | 17 |
GO:1904407 | Colorectum | AD | positive regulation of nitric oxide metabolic process | 17/3918 | 41/18723 | 2.29e-03 | 1.79e-02 | 17 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa051352 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa054172 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa051353 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
hsa054173 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa051354 | Colorectum | MSS | Yersinia infection | 53/1875 | 137/8465 | 7.73e-06 | 8.93e-05 | 5.47e-05 | 53 |
hsa054174 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa051602 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
hsa05167 | Colorectum | MSS | Kaposi sarcoma-associated herpesvirus infection | 60/1875 | 194/8465 | 2.59e-03 | 1.27e-02 | 7.81e-03 | 60 |
hsa05161 | Colorectum | MSS | Hepatitis B | 48/1875 | 162/8465 | 1.53e-02 | 4.93e-02 | 3.02e-02 | 48 |
hsa051355 | Colorectum | MSS | Yersinia infection | 53/1875 | 137/8465 | 7.73e-06 | 8.93e-05 | 5.47e-05 | 53 |
hsa054175 | Colorectum | MSS | Lipid and atherosclerosis | 70/1875 | 215/8465 | 2.38e-04 | 1.81e-03 | 1.11e-03 | 70 |
hsa051603 | Colorectum | MSS | Hepatitis C | 52/1875 | 157/8465 | 9.29e-04 | 5.58e-03 | 3.42e-03 | 52 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TICAM1 | SNV | Missense_Mutation | c.1231N>T | p.Arg411Trp | p.R411W | Q8IUC6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
TICAM1 | SNV | Missense_Mutation | c.1381N>C | p.Asp461His | p.D461H | Q8IUC6 | protein_coding | deleterious(0.01) | possibly_damaging(0.686) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
TICAM1 | SNV | Missense_Mutation | novel | c.868N>C | p.Thr290Pro | p.T290P | Q8IUC6 | protein_coding | tolerated(1) | benign(0) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
TICAM1 | deletion | Frame_Shift_Del | novel | c.183_190delAGAGGCAT | p.Ala63GlyfsTer40 | p.A63Gfs*40 | Q8IUC6 | protein_coding | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
TICAM1 | insertion | Frame_Shift_Ins | rs762126373 | c.1925_1926insC | p.Pro643ThrfsTer123 | p.P643Tfs*123 | Q8IUC6 | protein_coding | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
TICAM1 | deletion | Frame_Shift_Del | novel | c.455delN | p.Pro152GlnfsTer102 | p.P152Qfs*102 | Q8IUC6 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
TICAM1 | SNV | Missense_Mutation | novel | c.892N>G | p.Thr298Ala | p.T298A | Q8IUC6 | protein_coding | tolerated(0.53) | benign(0.006) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TICAM1 | SNV | Missense_Mutation | rs757840131 | c.2008C>A | p.Pro670Thr | p.P670T | Q8IUC6 | protein_coding | tolerated(0.41) | benign(0.01) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
TICAM1 | SNV | Missense_Mutation | rs780257437 | c.484C>G | p.Leu162Val | p.L162V | Q8IUC6 | protein_coding | tolerated(0.36) | benign(0.006) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TICAM1 | SNV | Missense_Mutation | c.192G>C | p.Leu64Phe | p.L64F | Q8IUC6 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
148022 | TICAM1 | TRANSCRIPTION FACTOR | VACCINE | 18217948 |
Page: 1 |